EGFR delE709-T710insD: A rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 7, Issue 10, 2012, Pages

  Ackerman, Allison ^a   Goldstein, Michael A ^a   Kobayashi, Susumu ^a   Costa, Daniel B ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEFITINIB; K RAS PROTEIN;

AGED; ANOREXIA; ARTICLE; CANCER STAGING; CASE REPORT; DRUG DOSE REDUCTION; DRUG ERUPTION; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENE DELETION; GENE INSERTION; GENE MUTATION; GENOTYPE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MULTIPLE PULMONARY NODULES; PRIORITY JOURNAL; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE; WILD TYPE;

EID: 84866627804     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182635ab4     Document Type: Article

References (6)

1. Gaughan EM, Costa DB. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol 2011;3:113-125.
2. Rosell R, Carcereny E, Gervais R, et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
3. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821.
4. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:e23-e31.
5. Wu SG, Chang YL, Lin JW, et al. Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS ONE 2011;6:e23303.
6. Yatabe Y, Pao W, Jett Jr. Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations. J Thorac Oncol 2012;7:775-776.